Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789143 | 0.96 | HRH4 (0.45) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL2479475 | 0.96 | HRH4 (0.45) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL19350614 | 0.96 | HRH4 (0.45) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL841330 | 0.96 | HRH4 (0.45) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL754871 | 0.96 | HRH4 (0.45) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL479263 | 0.92 | HRH4 (0.39) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL987491 | 0.87 | — | — | |
| SCHEMBL11044686 | 0.87 | CYP2C19 (0.48) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL12319688 | 0.87 | CYP2C19 (0.48) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL11293486 | 0.87 | EPHX1 (0.46) | HRH4HRH3ADRB2HTR1BNR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116920-A1 | PENTA- FUSED HEXA-HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | 杭州多域生物技术有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20200055883-A1 | CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-10246480-B2 | Compounds for the treatment of cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2018-06-14 | — | — | US | disclosed |
| US-9850183-B2 | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging | Reiley Pharmaceuticals, Inc. (US) | 2017-12-26 | — | — | US | disclosed |
| US-8372833-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-20120095231-A1 | UREA DERIVATIVE | YANO TOSHISADA (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8088777-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090203712-A1 | Urea Derivative | SHIONOGI &CO., LTD. | 2009-08-13 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-4720580-A | N-(aminoalkylene)benzenesulfonamides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-01-19 | — | — | US | disclosed |
| US-4340712-A | Process for the preparation of polyisocyanates containing biuret and/or higher polyuret groups and use thereof as synthesis component in the preparation of polyurethane plastics | BAYER AKTIENGESELLSCHAFT (DE) | 1982-07-20 | — | — | US | disclosed |
| EP-0012973-B1 | PROCESS FOR THE PREPARATION OF BI- AND/OR POLYURET-POLYISOCYANATES; PRODUCTS OBTAINED BY THIS PROCESS AND THEIR USE IN THE PREPARATION OF POLYURETHANES | BAYER AG (DE) | 1981-07-15 | — | — | EP | disclosed |
| EP-0012973-A1 | Process for the preparation of bi- and/or polyuret-polyisocyanates; products obtained by this process and their use in the preparation of polyurethanes | BAYER AG (DE) | 1980-07-09 | — | — | EP | disclosed |
| US-3943158-A | POLYURETHANE MONOMERS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | HRH4 2009/4885HRH3 2428/4885ADRB2 3654/4885 |
| US-20120095231-A1 | UREA DERIVATIVE | NPY5R, NPY1R, NPY2R | HRH4 90/4885HRH3 140/4885ADRB2 256/4885 |
| US-10246480-B2 | Compounds for the treatment of cancer | TP53, MYC, CDC73 | HRH4 3999/4885HRH3 3893/4885ADRB2 4482/4885 |
| US-20200055883-A1 | CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER | NME4, NME2, DPYD | HRH4 3249/4885HRH3 3513/4885ADRB2 4094/4885 |
| US-20090203712-A1 | Urea Derivative | NPY5R, NPY1R, NPY2R | HRH4 91/4885HRH3 145/4885ADRB2 263/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | HRH4 4031/4885HRH3 4422/4885ADRB2 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.